Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 367 clinical trials
featured
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement

The purpose of this study is to evaluate the safety and efficacy of pemigatinib plus pembrolizumab or pemigatinib alone versus the standard of care for participants with metastatic or unresectable urothelial carcinoma who are not eligible to receive cisplatin, are harboring FGFR3 mutation or rearrangement, and who have not received …

bladder carcinoma
bladder cancer
urothelial carcinoma
metastatic urothelial carcinoma
  • 28 views
  • 14 Dec, 2020
  • 64 locations
featured
Non-Muscle Invasive Bladder Cancer BOND-003

People with Non-Muscle Invasive Bladder Cancer are asked to participate in a research study being conducted by Montefiore Medical Center. 

radical cystectomy
bladder tumor
invasive bladder cancer
  • 0 views
  • 03 Aug, 2021
  • 1 location
featured
A Study to Evaluate INSTILADRIN® in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive NMIBC- Non muscle invasive bladder cancer

A Study to Evaluate INSTILADRIN® in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive NMIBC- Non muscle invasive bladder cancer

  • 142 views
  • 08 Nov, 2020
  • 1 location
featured
A multicenter clinical study of the Sonablate® 500 (Sonablate) for the TreAtment of locally Recurrent prostate cancer with HIFU(STAR Trial)

A multicenter clinical study of the Sonablate® 500 (Sonablate) for the TreAtment of locally Recurrent prostate cancer with HIFU(STAR Trial)

  • 196 views
  • 25 Mar, 2021
  • 1 location
Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients

This is an open-label, randomized, multicentric study in patients with high-risk non-muscle invasive bladder cancer who had never received BCG for this disease. The objective is to

bladder tumor
neutrophil count
aptt
transurethral resection
gilbert's syndrome
  • 0 views
  • 07 Apr, 2021
  • 30 locations
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

to treat patients with cancer of the urinary system (urothelial cancer). This type of cancer includes cancer of the bladder, renal pelvis, ureter or urethra. Some parts of the study will look at

bladder tumor
bcg vaccine
metastatic cancer
radical cystectomy
enfortumab vedotin
  • 284 views
  • 23 Jul, 2021
  • 93 locations
Atezolizumab and BCG in High Risk BCG na ve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)

Patients with high-risk non-muscle invasive bladder cancer (NMIBC) are usually managed by transurethral resection of their bladder tumor (TURBT) alone plus additional intravesical therapy to

carcinoma
carcinoma in situ
tumor cells
carcinoma of the bladder
bacillus calmette-guerin
  • 0 views
  • 25 Jan, 2021
Study of CAbozantinib in Combination With AtezolizumaB for Muscle-Invasive BladdEr Cancer

This is an open-label phase II study assessing the activity of cabozantinib combined with atezolizumab in patients with resectable muscle-invasive urothelial carcinoma who are ineligible for cisplatin-based therapy or decline cisplatin-based therapy. Each cycle equals 21 days. The dose of atezolizumab is 1200 mg IV flat dose every 3 weeks …

bladder tumor
carcinoma
cancer
radical cystectomy
neutrophil count
  • 0 views
  • 14 Jul, 2021
  • 4 locations
Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy

Immunotherapy (checkpoint inhibitors) is approved as first and second line treatment to patients with metastatic bladder cancer. However, response rates are low and no biomarkers have yet shown

bladder tumor
carcinoma
cancer
radical cystectomy
transitional cell carcinoma
  • 0 views
  • 27 Mar, 2021
  • 5 locations
Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer

The purpose of this study is to determine the good and bad effects of atezolizumab given in combination with a personalized cancer vaccine in patients with urothelial cancer either after surgery to remove organ where the tumor arose (for example, removal of the bladder) or for urothelial cancer that has …

poly iclc
carcinoma
metastatic urothelial carcinoma
low-molecular-weight heparin
metastasis
  • 7 views
  • 15 Mar, 2021
  • 1 location